Correction: TP53 drives invasion through expression of its Δ133p53β variant

Correction: TP53 drives invasion through expression of its Δ133p53β variant

Saved in:

Bibliographic Details
Main Authors:	Gilles Gadea, Nikola Arsic, Kenneth Fernandes, Alexandra Diot, Sebastien Joruiz, Samer Abdallah, Valerie Meuray, Stéphanie Vinot, Christelle Anguille, Judit Remenyi, Marie P Khoury, Philip R Quinlan, Colin A Purdie, Lee B Jordan, Frances V Fuller-Pace, Marion de Toledo, Maïlys Cren, Alastair M Thompson, Jean-Christophe Bourdon, Pierre Roux
Format:	Article
Language:	English
Published:	eLife Sciences Publications Ltd 2025-05-01
Series:	eLife
Online Access:	https://elifesciences.org/articles/107369
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

TP53 drives invasion through expression of its Δ133p53β variant
by: Gilles Gadea, et al.
Published: (2016-09-01)

TP63 as a modulator of ferroptosis in TP53 mutations glioblastoma
by: Haiping Cai, et al.
Published: (2025-08-01)

In-frame germline TP53 variant impairs p53 oligomerization and predisposes to cancer
by: Lucie Vanikova, et al.
Published: (2025-08-01)

A systematic analysis of the network of lncRNAs and mRNAs regulated by TP53 and TP53 mutants with hotspot mutations
by: Hong Chen, et al.
Published: (2025-07-01)

p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for TP53 Mutations in Gastrointestinal Neuroendocrine Neoplasms
by: Junjie Li, et al.
Published: (2021-01-01)

<i>TP53</i> Mutations in Chagasic Megaesophagus
by: Aparecida Perpetuo Fedossi Silveira, et al.
Published: (2025-03-01)

TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA
by: Ugo Testa, et al.
Published: (2023-06-01)

TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy
by: Yun Sun Lee, et al.
Published: (2018-08-01)

Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
by: Emma Haapaniemi, et al.
Published: (2019-08-01)

Impact of TP53 mutations on the efficacy of CAR-T cell therapy in cancer
by: Regina Mirgayazova, et al.
Published: (2024-12-01)

Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms
by: Qiang Ma, et al.
Published: (2024-12-01)

Δ133p53α and Δ160p53α isoforms of the tumor suppressor protein p53 exert dominant-negative effect primarily by co-aggregation
by: Liuqun Zhao, et al.
Published: (2025-07-01)

The Critical Role of TP53 in Developing Leukaemia in Human and Dogs, Review Article
by: ِAoula Al-Zebeeby, et al.
Published: (2025-06-01)

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults
by: Ethan J. Harris, et al.
Published: (2025-08-01)

Restoration of TP53 strategy via specific nanoparticles for ovarian cancer therapy
by: Menglei Zhang, et al.
Published: (2025-05-01)

Insights into an uncommon case: axillary extramammary Paget’s disease and TP53 mutation
by: Julia Zawistowska, et al.
Published: (2025-01-01)

TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC
by: Yun Sun Lee, et al.
Published: (2017-06-01)

MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis
by: Vishesh Khanna, et al.
Published: (2025-02-01)

Two Functional TP53 Genetic Variants and Predisposition to Keloid Scarring in Caucasians
by: Andrzej Dmytrzak, et al.
Published: (2019-01-01)

Essential thrombocytosis transformed AML with TP53 mutations and its clinical implications
by: Yang Si, et al.
Published: (2024-12-01)

Mosaic TP53 Mutation on Tumour Development in Pigs: A Case Study
by: Chommanart Thongkittidilok, et al.
Published: (2023-01-01)

The Influence of TP53 Expression on K562 Cell Lipid Metabolism and Differentiation
by: McKale Montgomery, et al.
Published: (2025-05-01)

TP53 Gene Mutations in Tumor Cells of Patients with Aggressive B-Cell Lymphomas
by: AE Misyurina, et al.
Published: (2019-05-01)

Iron overload mediates cytarabine resistance in AML by inhibiting the TP53 signaling pathway
by: Jia Yan, et al.
Published: (2025-02-01)

TP53 and KRAS co-mutations are associated with worse outcomes in mucinous ovarian carcinomas
by: Yingao Zhang, et al.
Published: (2025-08-01)

The relationship between TP53 Gene Mutation with treatment results in High-Grade Gliomas
by: Bac Thanh Nguyen, et al.
Published: (2024-05-01)

Identification and prognostic analysis of metabolic genes associated with TP53 mutation in multiple myeloma
by: Xiaoyan Tang, et al.
Published: (2024-12-01)

Molecular characteristics and clinical implications of TP53 mutations in therapy-related myelodysplastic syndromes
by: Zefei Bao, et al.
Published: (2025-04-01)

Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome
by: Mingyuan Du, et al.
Published: (2024-12-01)

Exploring the role of splicing in TP53 variant pathogenicity through predictions and minigene assays
by: Cristina Fortuno, et al.
Published: (2025-01-01)

Two ways to complex karyotype in MDS—the role of del(5q) and TP53
by: Sandra Huber, et al.
Published: (2025-05-01)

What have we learned about TP53-mutated acute myeloid leukemia?
by: Moazzam Shahzad, et al.
Published: (2024-11-01)

Differences in Gender and Overall Survival for Temperature-Sensitive TP53 Mutations in Gastroesophageal Cancer
by: Danial H. Shaikh, et al.
Published: (2024-11-01)

CircTP53/USP10/p53 signaling Axis as a Novel Regulator of Progression and Prognosis of Head and Neck Squamous Cell Carcinoma
by: Yin Wang, et al.
Published: (2025-08-01)

Oncogenic and teratogenic effects of Trp53Y217C, an inflammation-prone mouse model of the human hotspot mutant TP53Y220C
by: Sara Jaber, et al.
Published: (2025-04-01)

Defects in mitophagy promote redox‐driven metabolic syndrome in the absence of TP53INP1
by: Marion Seillier, et al.
Published: (2015-03-01)

A novel germline mutation of TP53 with breast cancer diagnosed as Li–Fraumeni syndrome
by: Masaya Kai, et al.
Published: (2022-10-01)

TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis
by: Jin Li, et al.
Published: (2025-01-01)

Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations
by: Anmol Baranwal, et al.
Published: (2025-07-01)

The TP53 Arg72Pro polymorphism predicts visual and neurodegenerative outcomes in retinal detachment
by: Nadia Galindo-Cabello, et al.
Published: (2025-05-01)